Secretome Therapeutics

Executive Summary

Secretome Therapeutics is a clinical-stage biotechnology company pioneering novel therapies derived from neonatal cardiac progenitor cells (nCPCs) to address cardiovascular diseases, including heart failure, dilated cardiomyopathy, and heart failure with preserved ejection fraction. The company's platform leverages the regenerative and immunomodulatory properties of ethically sourced neonatal cells through two lead assets: STM-01 (cell therapy) and STM-21 (secretome derivative). STM-01 is currently in Phase 1 clinical trials, evaluating safety and preliminary efficacy in patients with heart failure. The secretome-based STM-21 offers a potential off-the-shelf alternative, capitalizing on paracrine signaling mechanisms to promote cardiac repair. With a strong scientific foundation and a focus on high unmet medical needs, Secretome Therapeutics is positioned to disrupt the cardiovascular therapeutic landscape. As the company progresses its clinical programs, upcoming milestones include the completion and reporting of Phase 1 data for STM-01, which will inform dose selection and future trial design. Additionally, an IND filing for STM-21 is anticipated, expanding the pipeline into new indications and potentially accelerating development. The company's innovative approach and early clinical data could attract strategic partnerships or funding to support late-stage trials. Despite inherent risks in early-stage drug development, Secretome Therapeutics' unique platform and promising preclinical results provide a solid basis for continued investment and advancement.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 data readout for STM-01 in heart failure70% success
• Q3 2026IND filing for STM-21 secretome therapy80% success
• Q4 2026Strategic partnership or Series B funding announcement30% success